Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
Clinical trial NCT02986854 · COMPLETED
Trial details
- NCT number
- NCT02986854
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-08
- Primary completion
- 2017-07-17
- Enrollment
- 704
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.